Citations

Mayo Clinic

Showing 10 of 108602 citations.

Cochlear Implantation within One Month of Stereotactic Radiosurgery for Vestibular Schwannomas: A Retrospective Review
Plitt, Aaron , Dornhoffer, James R. , Driscoll, Colin L. W., Neff, Brian A., Carlson, Matthew L. , Link, Michael J.

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1762011 Get It

Extent of Surgical Resection as a Predictor of Disease Control in Skull Base Chordomas: A Multicenter Tumor Volumetric Analysis
Perez‐Vega, Carlos , Bendok, Bernard R. , Chaichana, Kaisorn L. , Quiñones‐Hinojosa, Alfredo , Akinduro, Oluwaseun O. , Ruiz-García, Henry , Gompel, Jamie J. Van

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761993 Get It

Angiographic Cross Filling between Inferior Petrosal Sinuses as a Factor Impacting ACTH Sampling in the Setting of Cushing's Disease
Rinaldo, Lorenzo , Young, William , Ransom, R. Chase, Martini, Michael L. , Carlstrom, Lucas P. , O’Keeffe, Derek T. , Young, William, Gompel, Jamie J. Van

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761986 Get It

Surgical Anatomy of the Foramen Lacerum and Its Ligaments: Anatomical Description and Clinical Relevance for Expanded Endonasal Approaches
Leonel, Luciano, Link, Michael J. , Peris‐Celda, Maria , Agosti, Edoardo , Serioli, Simona , Pinheiro‐Neto, Carlos

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761985 Get It

Anatomical Step-by-Step Dissection of Complex Skull Base Approaches for Trainees: Surgical Anatomy of the Endoscopic Endonasal Clivectomy, Odontoidectomy, and Far Medial Approach
Agosti, Edoardo, Yohan, Alex Y., Leonel, Luciano, Peris‐Celda, Maria , Agosti, Edoardo , Pinheiro‐Neto, Carlos

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761979 Get It

Intraoperatively Diagnosed Facial Schwannoma: A Multicenter Study of Incidence, Management, and Proposed Preoperative Imaging Protocol
Lewis, Daniel J. , Plitt, Aaron , Neff, Brian A., Hammerbeck-Ward, Charlotte , Driscoll, Colin L. W., Carlson, Matthew L. , Lloyd, Simon , Freeman, Simon , Potter, Gillian , Link, Michael J., Hannan, Cathal John , Lewis, Daniel, Richardson, George E. , King, Andrew Thomas , Gompel, Jamie J. Van , Pathmanaban, Omar Nathan , Link, Michael J. , Rutherford, Scott

Journal of Neurological Surgery Part B: Skull Base | March 20, 2023 | Volume: 84 | Issue: S 01 | Pages: S1-S344

10.1055/s-0043-1761971 Get It

Evaluation of Eculizumab Use in Renal Transplant Recipients
Norville, Kathryn , Stephen, Jenise, Mead‐Harvey, Carolyn , Corey, Rebecca, Votruba, Cassandra , Votruba, Cassandra D

Progress in Transplantation | March 20, 2023 | Volume: 33 | Issue: 2 | Pages: 162-167

10.1177/15269248231164163 | PMID 36940100 Get It

Introduction: Eculizumab is a monoclonal antibody that binds to complement protein C5, inhibiting complement-mediated thrombotic microangiopathy. It is approved for several indications including atypical hemolytic uremic syndrome. Additionally, eculizumab is used off-label for antibody-mediated rejection and C3 glomerulopathy in renal transplant recipients. Due to limited data available, the purpose of this study was to describe the use of eculizumab treatment in renal transplant recipients. Design: This retrospective single-center study evaluated the safety and efficacy of eculizumab for on- and off-label indications in renal transplant recipients. Adult renal transplant recipients receiving at least 1 dose of eculizumab posttransplant between October 2018 and September 2021 were included. The primary outcome evaluated was graft failure in patients treated with eculizumab. Results: Forty-seven patients were included in analysis. The median age at eculizumab initiation was 51 years [IQR 38-60], with 55% being female. Indications for eculizumab included atypical hemolytic uremic syndrome/thrombotic microangiopathy (63.8%), antibody-mediated rejection (27.7%), C3 glomerulopathy (4.3%), and other (4.3%). Graft failure occurred in 10 patients (21.3%) with a median of 2.4 weeks [IQR 0.5-23.3] from transplant to graft failure. At last follow-up (median 56.1 weeks), 44 (93.6%) patients were alive. After eculizumab initiation, renal function improved at 1 week, 1 month, and last follow-up. Conclusion: Eculizumab treatment demonstrated a benefit on graft and patient survival compared to reported incidence in thrombotic microangiopathy and antibody-mediated rejection. Due to the small sample size and retrospective design, further research is warranted to confirm these results.
Efficacy and safety of nintedanib in elderly patients with progressive fibrosing interstitial lung diseases (ILDs)*
Moua, Teng , Valenzuela, C, Wuyts, W.A., Miede, Corinna, Lievens, D., Bonella, Francesco , Okamoto, Masaki , Tomassetti, Sara , Valenzuela, C, Bendstrup, Elisabeth

Pneumologie | March 20, 2023 | Volume: 77 | Issue: S 01 | Pages: S57-S57

10.1055/s-0043-1761002 Get It

Patient-centered development ofEmbrace Pain: an online acceptance and commitment therapy intervention for cancer survivors with chronic painful chemotherapy-induced peripheral neuropathy
Graaf, Daniëlle L. van de , Smeets, Tom , Trompetter, Hester R. , Baars-Seebregts, Aafke, van de Graaf, Daniëlle L , Solberg Nes, Lise , Lee, Marije Liesbeth van der , Børøsund, Elin , Nes, Lise Solberg , Schreurs, Karlein M G , Mols, Floortje

Acta Oncologica | March 20, 2023 | Volume: 62 | Issue: 7 | Pages: 676-688

10.1080/0284186x.2023.2187260 | PMID 36939672 Get It

HER2 IHC Expression and Gene Amplification in p53-aberrant High-grade Endometrial Endometrioid Carcinoma Suggests That This Population May Benefit From HER2 Testing and Targeted Therapy
Joehlin‐Price, Amy , Komforti, Miglena K. , Ladwig, Nicholas R. , Devine, Patrick J., Hoyle, Carrie, McCoy, Lauren, Sprague, Cathy, Astbury, Caroline , Chen, Yunn‐Yi , Garg, Karuna , Devine, Patrick, McCoy, Lauren, Hoda, Raza S.

American Journal of Surgical Pathology | March 20, 2023 | Volume: 47 | Issue: 5 | Pages: 580-588

10.1097/pas.0000000000002030 | PMID 36939053 Get It

Among gynecologic cancers, uterine serous carcinoma (USC) has been shown to be human epidermal growth factor receptor 2 (HER2) amplified and trastuzumab has been included in the recent National Comprehensive Cancer Network (NCCN) guidelines for treatment of advanced stage or recurrent USC with HER2 overexpression/amplification. There is limited literature suggesting that a subset of high-grade endometrioid carcinomas with aberrant p53 expression may also be HER2 amplified and these patients could benefit from the addition of targeted therapy. We identified 59 p53-aberrant (mismatch repair proficient) FIGO 3 endometrioid carcinomas of the uterus. HER2 immunohistochemistry was performed in all 59 tumors and HER2 fluorescence in situ hybridization (FISH) was performed in 52 of the 59 cases. Four of the 59 cases were HER2 3+ by immunohistochemistry (6.7%), using the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) 2007, 2013, and 2018 criteria. HER2 FISH was performed in 3 of the 4 cases and was amplified in all 3. Nine, 8, and 7 tumors showed 2+ HER2 staining when applying 2018, 2013, and 2007 criteria, respectively, FISH was performed in 7 tumors and none were amplified. An additional 4 cases did not perfectly meet the 2018 ASCO/CAP criteria but were assigned a score of 2+, none were amplified by HER2 FISH. The remaining 42 cases showed 1+ or no staining for HER2, FISH was successfully performed in 38 tumors and none showed amplification. Approximately half of the tumors fulfilled criteria for HER2-low or HER2-very low (10 HER2-low and 20 HER2-very low). Our data shows that a subset of p53-aberrant high-grade endometrial endometrioid carcinoma express HER2 and these patients may benefit from the addition of targeted therapy. The role of targeted therapy in HER2-low gynecologic carcinoma is currently unexplored.